Hospital
Sunrise Mountainview Hospital, INC.
Sunrise Mountainview Hospital, INC. was paid $5.20M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99285, emergency room visit (most serious) — 23% of everything it billed.
33Billing provider infoSUNRISE MOUNTAINVIEW HOSPITAL, INC.
LAS VEGAS, NV 89128
LAS VEGAS, NV 89128
33aNPI1013961093assigned 05/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.20M
24GClaims453,585
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#21 of 36
Median peer was paid$7.64M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,921 | $792K | |
| 2019 | 97,788 | $1.02M | |
| 2020 | 70,402 | $693K | |
| 2021 | 60,261 | $704K | |
| 2022 | 56,664 | $686K | |
| 2023 | 60,511 | $770K | |
| 2024incomplete | 29,038 | $536K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 8,986 | 6,981 | $1.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 19,826 | 16,183 | $1.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 16,240 | 13,862 | $801K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 15% | 4,194 | 3,332 | $781K |
| 70450 | Computed tomography, head or brain; without contrast material | 9.0% | 5,165 | 4,336 | $468K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 4.5% | 1,369 | 1,084 | $232K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.4% | 1,313 | 1,126 | $175K |
| G0378 | Hospital observation service, per hour | 2.1% | 5,455 | 3,690 | $107K |
| 93975 | 2.0% | 356 | 273 | $105K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 2,049 | 735 | $67K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,016 | 1,767 | $50K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,641 | 1,420 | $25K |
146 more codes
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 352 | $23K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 56 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,526 | $13K |
| 93970 | <1% | 154 | $10K | |
| 87040 | <1% | 7,567 | $9K | |
| 78492 | <1% | 33 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,259 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 340 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,562 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,932 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 459 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,612 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,546 | $3K |
| 93976 | <1% | 559 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,474 | $3K |
| 85027 | <1% | 35,767 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,733 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 489 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,529 | $1K |
| 97163 | <1% | 1,140 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,179 | $1K |
| 93971 | <1% | 562 | $1K | |
| 80076 | <1% | 9,624 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 214 | $967.40 |
| 84484 | <1% | 18,928 | $928.69 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,154 | $886.47 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,964 | $819.68 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 649 | $747.41 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 139 | $746.74 |
| 84703 | <1% | 7,365 | $697.32 | |
| 83880 | <1% | 5,837 | $668.88 | |
| 87088 | <1% | 3,326 | $652.45 | |
| 81001 | <1% | 12,735 | $644.33 | |
| 80047 | <1% | 8,721 | $640.47 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,329 | $633.18 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,460 | $617.80 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,114 | $567.34 |
| 87070 | <1% | 669 | $562.20 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 605 | $526.68 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 606 | $502.74 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,389 | $492.84 |
| 80053 | Comprehensive metabolic panel | <1% | 17,805 | $457.43 |
| 84702 | <1% | 1,462 | $401.22 | |
| 76830 | Ultrasound, transvaginal | <1% | 351 | $391.60 |
| 83690 | <1% | 9,544 | $388.93 | |
| 82550 | <1% | 7,631 | $358.34 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 62 | $345.99 |
| 73564 | <1% | 360 | $333.20 | |
| 83605 | <1% | 3,365 | $317.20 | |
| 80069 | <1% | 179 | $301.60 | |
| 96376 | <1% | 2,218 | $281.92 | |
| 85610 | <1% | 14,599 | $281.33 | |
| 85730 | <1% | 11,333 | $240.70 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 65 | $231.15 |
| 86850 | <1% | 2,311 | $226.61 | |
| 72100 | <1% | 383 | $210.25 | |
| 81025 | <1% | 2,249 | $198.24 | |
| 73630 | <1% | 426 | $194.71 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 334 | $187.96 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,288 | $180.31 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,152 | $166.91 |
| 73130 | <1% | 142 | $156.60 | |
| 86920 | <1% | 61 | $151.80 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 266 | $145.75 |
| 97161 | <1% | 35 | $141.10 | |
| 74018 | <1% | 226 | $139.19 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 214 | $128.28 |
| 83735 | <1% | 5,337 | $123.39 | |
| 97162 | <1% | 68 | $99.58 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 350 | $98.16 |
| 86900 | <1% | 3,267 | $87.24 | |
| 86901 | <1% | 3,268 | $85.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,945 | $83.57 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,884 | $83.42 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,207 | $79.92 |
| 85379 | <1% | 595 | $78.45 | |
| 82805 | <1% | 223 | $77.44 | |
| 84439 | <1% | 864 | $67.65 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 275 | $60.25 |
| 82330 | <1% | 61 | $59.41 | |
| 87210 | <1% | 753 | $52.21 | |
| 81003 | <1% | 2,202 | $51.92 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,214 | $51.01 |
| 82553 | <1% | 384 | $47.28 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,286 | $45.33 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,229 | $45.22 |
| 82248 | <1% | 3,349 | $35.57 | |
| 73030 | <1% | 378 | $33.36 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 680 | $31.55 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,536 | $30.72 |
| 85049 | <1% | 28 | $29.55 | |
| 87186 | <1% | 634 | $29.50 | |
| 73610 | <1% | 150 | $26.85 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 534 | $25.30 |
| 82140 | <1% | 565 | $25.30 | |
| 84100 | <1% | 1,691 | $19.38 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 476 | $18.57 |
| 80061 | Lipid panel | <1% | 1,023 | $18.28 |
| 86140 | <1% | 264 | $17.65 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,343 | $17.35 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 99 | $16.74 |
| 87430 | <1% | 295 | $16.36 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 259 | $11.31 |
| 83050 | <1% | 14 | $10.00 | |
| 85652 | <1% | 161 | $7.40 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 62 | $5.00 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,167 | $4.33 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,644 | $3.75 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 311 | $3.48 |
| 87205 | <1% | 38 | $2.91 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 193 | $2.52 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 785 | $0.89 |
| S0028 | Injection, famotidine, 20 mg | <1% | 170 | $0.88 |
| A9270 | Non-covered item or service | 0% | 10,555 | $0.00 |
| 11045 | 0% | 115 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 359 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 287 | $0.00 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 0% | 365 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 24 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 116 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 645 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 153 | $0.00 |
| 36430 | 0% | 35 | $0.00 | |
| 73502 | 0% | 61 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 17 | $0.00 |
| 96368 | 0% | 50 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 106 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 44 | $0.00 |
| C1769 | Guide wire | 0% | 13 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 50 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 28 | $0.00 |
| J3490 | Unclassified drugs | 0% | 88 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 15 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 14 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 57 | $0.00 |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 0% | 33 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 66 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 66 | $0.00 |
| 86923 | 0% | 16 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 247 | $0.00 |
| 93017 | 0% | 160 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 39 | $0.00 |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 0% | 39 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 19 | $0.00 |
| 97167 | 0% | 20 | $0.00 | |
| 87631 | 0% | 93 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKILLIAN, STEVE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sunrise Mountain View Hospital, INC. | North Las Vegas, NV | $770K |
| Sunrise Mountainview Hospital, INC. | Las Vegas, NV | $75K |
| Sunrise Mountainview Hospital, INC. | Las Vegas, NV | $4.42 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.